Related Experiment Video

Updated: Jun 18, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Anticancer activity of a new gonadotropin releasing hormone analogue

Mohammad Mirzaei Saleh-Abady1, Hossein Naderi-Manesh, Abdolali Alizadeh

  • 1Department of Biophysics, Faculty of Basic Science, Tarbiat Modares University, Tehran, Iran.

Biopolymers
|November 13, 2009
PubMed

Insights

A novel gonadotropin-releasing hormone (GnRH) analogue shows significant anticancer activity by inhibiting cancer cell proliferation and inducing apoptosis. This new GnRH analogue demonstrates superior efficacy compared to triptorelin, suggesting its potential as a pharmaceutical candidate.

Area of Science:

  • Reproductive biology
  • Oncology
  • Pharmacology

Background:

  • Gonadotropin-releasing hormone (GnRH) plays a key role in reproduction.
  • GnRH and its receptor act in extrapituitary sites to regulate cell proliferation, exhibiting anticancer properties.
  • Previous research suggests GnRH's potential in cancer therapy.

Purpose of the Study:

  • To investigate the anticancer activity of a new GnRH analogue.
  • To compare its efficacy against established GnRH analogues like triptorelin.
  • To elucidate the mechanisms underlying its anticancer effects.

Main Methods:

  • Testing the new GnRH analogue on human breast and ovarian cancer cell lines.
  • Dose-response studies to determine inhibitory effects.
  • Analysis of apoptotic mechanisms and protease stability.

Main Results:

  • The new GnRH analogue dose-dependently inhibited proliferation of breast and ovarian cancer cells.
  • Its inhibitory efficiency was higher than that of triptorelin.
  • Apoptosis was identified as a mechanism of action.
  • Enhanced protease stability was observed compared to triptorelin.

Conclusions:

  • The new GnRH analogue possesses significant anticancer activity.
  • It exhibits superior efficacy and improved stability over triptorelin.
  • This analogue is a promising pharmaceutical candidate for cancer treatment.

More Related Videos

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Gonadal and Placental Hormones01:24

Gonadal and Placental Hormones

The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.